Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition

Abstract

Non-small cell lung cancers (NSCLC) that have developed resistance to EGF receptor (EGFR) tyrosine kinase inhibitor (TKI), including gefitinib and erlotinib, are clinically linked to an epithelial-to-mesenchymal transition (EMT) phenotype. Here, we examined whether modulating EMT maintains the responsiveness of EGFR-mutated NSCLCs to EGFR TKI therapy. Using human NSCLC cell lines harboring mutated EGFR and a transgenic mouse model of lung cancer driven by mutant EGFR (EGFR-Del19-T790M), we demonstrate that EGFR inhibition induces TGFb secretion followed by SMAD pathway activation, an event that promotes EMT. Chronic exposure of EGFR-mutated NSCLC cells to TGFb was sufficient to induce EMT and resistance to EGFR TKI treatment. Furthermore, NSCLC HCC4006 cells with acquired resistance to gefitinib were characterized by a mesenchymal phenotype and displayed a higher prevalence of the EGFR T790M mutated allele. Notably, combined inhibition of EGFR and the TGFb receptor in HCC4006 cells prevented EMT but was not sufficient to prevent acquired gefitinib resistance because of an increased emergence of the EGFR T790M allele compared with cells treated with gefitinib alone. Conversely, another independent NSCLC cell line, PC9, reproducibly developed EGFR T790M mutations as the primary mechanism underlying EGFR TKI resistance, even though the prevalence of the mutant allele was lower than that in HCC4006 cells. Thus, our findings underscore heterogeneity within NSCLC cells lines harboring EGFR kinase domain mutations that give rise to divergent resistance mechanisms in response to treatment and anticipate the complexity of EMT suppression as a therapeutic strategy. Cancer Res; 75(20); 4372-83. Ó2015 AACR.

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells

“…We have shown that HCC4006ER cells were insensitive to anti-microtubule agents that are often used as cytotoxic agents in non-small cell lung cancers [28]. These results may indicate that EMT is one of the most intractable cancer status, and treatment strategies that may prevent EMT (or downregulation of E-cadherin), such as upfront polytherapy as recently reported [30, 44, 45], may be needed in future development of treatment strategies.…”

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma

“…Indeed, among EGFR-mutant lung cancers with acquired resistance to their initial EGFR inhibitor, there is growing evidence that all resistant cells may not share the same, but exhibit different resistance mechanisms, likely reflecting both intratumoural and intertumoural heterogeneity, as well as dynamic changes in the relative populations of resistant clones over time143637. This problem adds to the potential benefit of blocking resistance with up-front combination approaches.…”

The aqueous extract of <em>Brucea javanica</em> suppresses cell growth and alleviates tumorigenesis of human lung cancer cells by targeting mutated epidermal growth factor receptor

“…EGFR mutation at L858R is a prerequisite for drug sensitivity 9. This specific mutation site appears in a restricted subset of NSCLC patients that includes those of East Asian ethnicity, women, and nonsmoking individuals 10. However, patients receiving tailored target therapy gradually develop secondary mutations in EGFR, which results in relapse 11.…”